Ascendis Pharma A (ASND) EBT (2014 - 2026)

Ascendis Pharma A has disclosed EBT across 13 years of filings, most recently posting -$56.4 million for Q1 2026.

• EBT for Q1 2026 came in at -$56.4 million, up 42.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$194.2 million (up 46.61% YoY), and the FY2025 annual result was -$247.5 million, up 37.94% from the prior year.
• EBT came in at -$56.4 million for Q1 2026 at Ascendis Pharma A, down from -$31.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$31.1 million in Q4 2025 to a low of -$206.2 million in Q4 2022.
• The 5-year median for EBT is -$107.8 million (2024), against an average of -$106.8 million.
• Across the five-year window, EBT sank 85.04% in 2022 and jumped 66.29% in 2025, its largest moves.
• Ascendis Pharma A's EBT stood at -$206.2 million in 2022, then jumped by 57.68% to -$87.2 million in 2023, then soared by 54.21% to -$39.9 million in 2024, then climbed by 22.19% to -$31.1 million in 2025, then plunged by 81.44% to -$56.4 million in 2026.
• The last three EBT figures came in at -$56.4 million (Q1 2026), -$31.1 million (Q4 2025), and -$67.1 million (Q3 2025), per Business Quant data.